# US 2025/0188183 A1 · Use of protocadherins in methods of diagnosing and treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0188183 A1
- Document ID: US20250188183A1
- Status: Published application
- Kind: A1
- Application number: 18/279,962
- Filed: 2022-03-02
- Published: 2025-06-12
- Earliest claimed: 2021-03-02
- Assignees: Reverse BioEngineering, Inc.
- Applicants: Reverse Bioengineering, Inc.
- Inventors: Michael D. West
- Web page: https://patentgrep.com/patent/US20250188183A1

## CPC

- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4254: {Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/3015: {Breast}
- C07K 16/3023: {Lung}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions and methods are disclosed for targeting the clustered protocadherins for therapeutic effect. More specifically, compositions and methods are disclosed to modify select isoforms in the α, β, and γ cluster to promote tissue regeneration or to target and reduce tumor burden in diverse cancer types. The methods have application in veterinary and human medicine.

## Claims

### Claim 1

A method for treating cancer in a subject, a method comprising steps: 1) obtaining a biological sample from the subject comprising cancer cells; 2) identifying cancer cells that exhibit an embryonic phenotype; 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype; and 4) administering to the subject an anti-cancer vaccine comprising an antigen, thereby inducing an immune response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the identified one or more isoforms are members of the alpha cluster protocadherins and/or beta cluster protocadherins.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more isoforms are PCDHA1, PCDHA3, PCDHA6, PCDHB3, or a combination thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-cancer vaccine is mRNA.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mRNA encodes one or more isoforms of the alpha cluster protocadherins and/or beta cluster protocadherins.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mRNA encodes PCDHA1, PCDHA3, PCDHA6, PCDHB3, or a combination thereof.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the anti-cancer vaccine is one or more polypeptides of isoforms of the alpha cluster protocadherins and/or beta cluster protocadherins, or fragments thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more polypeptides are PCDHA1, PCDHA3, PCDHA6, PCDHB3, fragments thereof, or a combination thereof.

### Claim at position 11

-21. (canceled)

### Claim 22

A method for inducing an immune response against mammalian cancer cells in a subject, comprised of the steps: 1) obtaining a biological sample from the subject comprising cancer cells; 2) identifying cancer cells that exhibit an embryonic phenotype; 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype; and 4) administering to the subject genetically-modified immune cells capable of generating an immune response to the cancer in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the identified one or more isoforms are PCDHA1, PCDHA3, PCDHA6, PCDHB3, or a combination thereof.

### Claim 24 (depends on 22)

The method of claim 22, wherein the genetically-modified immune cells comprise an antigen-binding domain, wherein the antigen-binding domain binds PCDHA1, PCDHA3, PCDHA6, PCDHB3, fragments thereof, or a combination thereof.

### Claim at position 15

-28. (canceled)

### Claim 29 (depends on 22)

The method of claim 22, wherein the genetically-modified immune cells are Chimeric Antigen Receptor T-cells (CAR T-cells).

### Claim 30 (depends on 29)

The method of claim 29, wherein the CAR comprises an antigen binding domain that binds an isoform of the clustered protocadherin locus expressed in the cancer cell.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The method of claim 30, wherein the isoform are PCDHA1, PCDHA3, PCDHA6, PCDHB3, fragment thereof, or a combination thereof.

### Claim at position 20

-35. (canceled)

### Claim 36

A method for inducing an immune response against mammalian cancer cells in a subject, comprised of the steps: 1) obtaining a biological sample from the subject comprising cancer cells; 2) identifying cancer cells that exhibit an embryonic phenotype; 3) identifying one or more isoforms of a clustered protocadherin locus expressed in the cancer cell that exhibit an embryonic phenotype; and 4) administering to the subject an immunoglobulin superfamily member to direct an immune response specifically to the cancer cells.

### Claim 37 (depends on 36)

The method of claim 36, wherein the one or more isoforms identified in the cancer cells are PCDHA1, PCDHA3, PCDHA6, PCDHB3, or a combination thereof.

### Claim 38 (depends on 36)

The method of claim 36, wherein the immunoglobulin superfamily member is a monoclonal or polyclonal antibody.

### Claim 39 (depends on 38)

The method of claim 38, wherein the antibody binds PCDHA3 or PCDHB3.

### Claim at position 25

-53. (canceled)

### Claim 54 (depends on 1)

The method of claim 1, wherein the method further comprises administering a chemotherapeutic agent to the subject.

### Claim 55 (depends on 54)

The method of claim 54, wherein the chemotherapeutic agent is a DNA damaging agent, checkpoint inhibitor, antibody, alkylating agent, antimetabolites, anthracyclines, nitrosoureas, topisomerase inhibitor, isomerase inhibitor, mitotic inhibitor, tyrosine kinase inhibitors, protease inhibitor, or a combination thereof.

### Claim at position 28

-57. (canceled)

### Claim 58 (depends on 1)

The method of claim 1, wherein the cancer is B cell cancer, melanomas, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of hematologic tissues, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bone cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, polycythemia vera, lymphoma, multiple myeloma, bladder cancer, colon cancer, gynecologic cancers, renal cancer, laryngeal cancer, oral cancer, head and neck cancer, or skin cancer.

### Claim at position 30

-60. (canceled)
